Proactive Investors - Run By Investors For Investors

Breakfast News - Polarean Imaging, Tissue Regenix, AFH Financial and more...

Breakfast News - Polarean Imaging, Tissue Regenix, AFH Financial and more...

Set menu


Total number of AIM Companies (Incl Susp):


Total number of AIM Companies trading:


*as at close of business  09 November 2018

Standard List**  of Main Market:

Total number of Standard List Companies

(Incl Susp):


Total number of Standard List Companies trading:


*as at close of business 09 November 2018

NEX Growth Market:

Total number of NEX Growth Market Companies (Incl Susp):


Total number of NEX Growth Market Companies trading:


*as at close of business 09 November 2018                           

*A corporate client of Hybridan LLP

**  Standard Listing as defined by Hybridan LLP to be a business with strictly operational activity


Dish of the day

Gresham House Energy Storage Fund, has joined the Main Market today raising £100m, the Fund will be managed by the New Energy division of Gresham House Asset Management, the specialist renewable and storage asset manager.   

Off the menu      

No Leavers Today              

Banquet Buffet

Polarean Imaging (LON:POLX) 17.5p £13.33m

The Company announced that it has entered into a licencing agreement with Duke University for patents related to an entirely new use for hyperpolarised gas imaging in the field of pulmonary vascular disease ('PVD'). This opens the potential for Polarean to address an additional unmet medical need in diagnosis and monitoring of cardiopulmonary conditions. 

Duke University has recently patented a method of using hyperpolarised gas MRI in a novel, non-invasive manner to quantify pulmonary vascular pressure, potentially eliminating the need for the costly and invasive catheterisation required to confirm PVD and monitor its progression. 

The licencing agreement with Duke University grants Polarean exclusive rights to the technology, and the Company will work with Duke to drive this new technology towards clinical use and regulatory approval. This license further strengthens the previous licensing of Duke's 3D gas exchange imaging technology to provide a complete diagnostic suite that addresses a critical unmet need in the care of patients with PVD.

Andalas Energy (LON:ADL)  0.95p £3.47m

Andalas Energy and Power, reported that Corallian Energy Limited, the Exploration Operator for Licence P1918, has informed the JV partners that the Department for Business, Energy and Industrial Strategy, Offshore Petroleum Regulator for Environment and Decommissioning (OPRED) has advised the Oil and Gas Authority of its in principle agreement to the issue of the relevant consent for the Colter well, in which Andalas has an 8% interest.

There are several regulatory approvals and notifications still required before the consenting process is completed for the work programme. When all the necessary approvals have been obtained, Corallian expects to commence a two-well work programme, with the drilling of the Wick well (in which Andalas does not have an interest) expected to commence during Dec 2018. Following completion of the Wick well, the rig will be mobilised from the Moray Firth to the English Channel to drill the Colter well.

EVR Holdings (LON:EVRH) 5.75p £79.47m

EVR Holdings, the leading creator of virtual reality music content and operator of the MelodyVR platform, announced that it has entered into a content licensing agreement with Anomaly Partners LA, LLC. Anomaly is a leading advertising agency with offices in Los Angeles, New York, Toronto, London, Amsterdam and Shanghai.

As part of the agreement, MelodyVR will license a number of its assets, such as VR content (including audio recordings and audio-visual footage), images and music, in addition to the MelodyVR brand assets such as, logos, trademarks and other distinctive brand features of MelodyVR. The assets will be licensed for exploitation across various platforms including television (broadcast, cable, satellite and on-demand), industrial (including cinema), digital/online media, social media and OOH advertising.

As part of the agreement MelodyVR will receive a material revenue contribution in respect of the licensing fee and has received a number of marketing commitments from the advertiser; Facebook Technologies, LLC.  MelodyVR will provide further updates as the advertising campaign progresses.

Frenkel Topping (LON:FEN) 27.5p £19.28m

Frenkel Topping, a specialist independent financial advisor and asset manager focussed on asset protection for vulnerable clients, made the following trading update:

The Company announced that trading has been positive year to date and as a result the Company is currently trading in line with management expectations for the full year to 31 Dec 2018.

The Company has benefited from a number of new asset management and expert witness mandates, secured in the second half of the financial year. These wins reflect the significant investment made by the Company over the last 12 months, including the launch of the Frenkel Topping Training Academy to deepen its talent pool and nurture home grown skills.

Frenkel Topping's Expert Witness revenue has exceeded its annual target, an encouraging indication of future AUM growth as it enters 2019 and beyond. The complete pre-settlement service provides expert witnesses to work with clients with personal injury and clinical negligence damages settlements.

One Media iP (LON:OMIP) 6.42p £8.71m 

One Media IP Group, the digital media content provider that exploits intellectual property rights around music, video and copyright technology, provided the following update on trading.

At the time of the Company’s Interim Results, the Board reported continued strong trading and healthy cash position. Following the recent successful fundraising, the current period is pivotal as the Company continues to exploit and take full advantage of the ongoing shift towards streaming.

Before related fundraising transaction costs, the Board is pleased to report that trading is in line with expectations for the year ended 31 Oct 2018.

Coral Products (LON:CRU) 10.75p £8.47m

Coral Products, a specialist in the design, manufacture and supply of plastic products based in Haydock, Merseyside, announced that further to the Company's announcement of 8 Aug 2018, the Company's Haydock Mouldings Division has received a further order of £795,000 in relation to the supply contract for totes for the customer's UK fulfilment centres.

The previous extensions have had a positive effect on sales and performance at Haydock Mouldings, and the further orders are expected to continue this trend into the fourth quarter of Coral's current financial period ending on 30 April 2019.

Tissue Regenix (LON:TRX) 7.75p £84.95m

Tissue Regenix Group, the regenerative medical devices company announced that its subsidiary 'CellRight Technologies', has entered into an agreement, effective immediately, allowing Arthrex, Inc. to distribute its proprietary 'BioRinse' bone portfolio throughout Europe, with the initial focus on the UK.

This new agreement builds on the existing US relationship signed in March 2018 and is a direct result of   the collaborative work that Arthrex and Tissue Regenix have been undertaking to evaluate additional business opportunities.

Sareum Holdings* (LON:SAR) 0.78p £22.29m

Sareum, the specialist small molecule drug development company, announced the appointments of Michael Owen, PhD and Clive Birch as NEDs.

Michael Owen (67) has worked in biomedical research, and in the pharmaceutical and biotechnology industries for nearly 40 years. He is the co-founder and first CSO of Kymab Ltd, a biopharmaceutical company based in Cambridge, UK, prior to which he worked for GSK where he was SVP and Head of Research for Biopharmaceuticals R&D.

Clive Birch (65) is an Independent NED of Cambridge Innovation Capital plc, a Cambridge-based builder of technology and healthcare companies. He is a retired partner of PricewaterhouseCoopers where his role was that of an auditor and reporting accountant with an industry specialism in early stage technology and healthcare companies. 

AFH Financial (LON:AFHP) 393p £165.58m

The Board of AFH, a leading financial planning led wealth management firm,  announced the completion of the acquisition of CWP Financial Services Limited based in Ashford, Kent. Following the acquisition Bob Perry will retire and the clients of CWP will be serviced by existing AFH advisers.

Under the terms of the acquisition, the maximum purchase price is £0.89m based on the ongoing recurring revenue of the business subject to the fulfilment of certain financial targets.


The initial consideration for the acquisition is £0.47m in cash, funded from the Company's existing cash resources. Further deferred consideration will be payable in cash over the next 26 months in two tranches, dependent upon performance criteria of the business acquired.

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use